The world of immunotherapy in multiple myeloma is exploding - with new treatments being FDA-approved and others working their way through the FDA approval process. In this show, Dr. Paul Richardson focuses on the innovation in immunotherapy that we've seen in the first half of 2025. This includes a discussion about CAR T, bispecific and trispecific antibodies, and a deeper dive on a new class of drugs in myeloma called Antibody Drug Conjugates, with a drug called belantamab mafodotin going through the FDA review process, with a hopeful approval in October of this year.